|
WO2021055811A1
|
|
Cap guides and methods of use thereof for rna mapping
|
|
WO2021055833A1
|
|
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2021055849A1
|
|
Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2021055835A1
|
|
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2021050986A1
|
|
Lnp-formulated mrna therapeutics and use thereof for treating human subjects
|
|
WO2021050864A1
|
|
Human cytomegalovirus vaccine
|
|
WO2021030533A1
|
|
Processes for purifying downstream products of in vitro transcription
|
|
WO2021022173A1
|
|
Compositions and methods for delivery of rna interference agents to immune cells
|
|
WO2020263985A1
|
|
Messenger rna comprising functional rna elements and uses thereof
|
|
WO2020263883A1
|
|
Endonuclease-resistant messenger rna and uses thereof
|
|
WO2020243561A1
|
|
Expanded t cell assay
|
|
WO2020227615A1
|
|
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
WO2020227690A1
|
|
Methods of using lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide and pharmaceutical compositions comprising the same
|
|
WO2020227642A1
|
|
Compositions for skin and wounds and methods of use thereof
|
|
WO2020227510A1
|
|
Polynucleotides for disrupting immune cell activity and methods of use thereof
|
|
WO2020227537A1
|
|
Differentially expressed immune cell micrornas for regulation of protein expression
|
|
WO2020190750A1
|
|
Hiv rna vaccines
|
|
WO2020185811A1
|
|
Fed-batch in vitro transcription process
|
|
WO2020172239A1
|
|
Rna polymerase variants for co-transcriptional capping
|
|
WO2020160397A1
|
|
Methods of preparing lipid nanoparticles
|
